USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma.

[1]  K. Trinkaus,et al.  Pacritinib to inhibit JAK/STAT signaling in refractory metastatic colon and rectal cancer. , 2017, Journal of gastrointestinal oncology.

[2]  Jing Yang,et al.  Study on the association between PI3K/AKT/mTOR signaling pathway gene polymorphism and susceptibility to gastric cancer. , 2017, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[3]  B. Groner,et al.  Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition , 2017, Molecular and Cellular Endocrinology.

[4]  W. Gong,et al.  LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells , 2017, Oncogene.

[5]  Haiyang Xie,et al.  USP22 mediates the multidrug resistance of hepatocellular carcinoma via the SIRT1/AKT/MRP1 signaling pathway , 2017, Molecular oncology.

[6]  M. Tsao,et al.  TGFβ engages MEK/ERK to differentially regulate benign and malignant pancreas cell function , 2017, Oncogene.

[7]  Guohua Liu,et al.  Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma. , 2017, Oncology letters.

[8]  D. Gerlier,et al.  Assessing mycoplasma contamination of cell cultures by qPCR using a set of universal primer pairs targeting a 1.5 kb fragment of 16S rRNA genes , 2017, PloS one.

[9]  L. Cai,et al.  Mammalian Eps15 homology domain 1 promotes metastasis in non-small cell lung cancer by inducing epithelial-mesenchymal transition , 2016, Oncotarget.

[10]  E. Maspero,et al.  USP9X Controls EGFR Fate by Deubiquitinating the Endocytic Adaptor Eps15 , 2016, Current Biology.

[11]  Zhaojian Liu,et al.  Ubiquitin-specific protease 22 is a deubiquitinase of CCNB1 , 2015, Cell Discovery.

[12]  Wei Liu,et al.  USP22 promotes tumor progression and induces epithelial-mesenchymal transition in lung adenocarcinoma. , 2015, Lung cancer.

[13]  Aleksandra Markovets,et al.  Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M , 2015, Nature Medicine.

[14]  M. Loda,et al.  The ubiquitin-specific protease USP2a prevents endocytosis-mediated EGFR degradation , 2013, Oncogene.

[15]  A. Letai,et al.  Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. , 2012, Cancer discovery.

[16]  L. Cai,et al.  Expression patterns of USP22 and potential targets BMI-1, PTEN, p-AKT in non-small-cell lung cancer. , 2012, Lung cancer.

[17]  Jianxun Song,et al.  USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development. , 2012, Molecular cell.

[18]  M. Kris,et al.  Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Yvonne A. Evrard,et al.  Gcn5 and SAGA regulate shelterin protein turnover and telomere maintenance. , 2009, Molecular cell.

[20]  M. Somerfield,et al.  American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  G. Tortora,et al.  EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.

[22]  M. Komada.  Controlling receptor downregulation by ubiquitination and deubiquitination. , 2008, Current drug discovery technologies.

[23]  Claude C. Warzecha,et al.  The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. , 2008, Molecular cell.

[24]  A. Sorkin,et al.  EGF receptor ubiquitination is not necessary for its internalization , 2007, Proceedings of the National Academy of Sciences.

[25]  K. Knobeloch,et al.  Essential Role of Ubiquitin-Specific Protease 8 for Receptor Tyrosine Kinase Stability and Endocytic Trafficking In Vivo , 2007, Molecular and Cellular Biology.

[26]  S. Gygi,et al.  Targeting of AMSH to Endosomes Is Required for Epidermal Growth Factor Receptor Degradation* , 2007, Journal of Biological Chemistry.

[27]  J. E. V. van Leeuwen,et al.  UBPY-mediated Epidermal Growth Factor Receptor (EGFR) De-ubiquitination Promotes EGFR Degradation* , 2007, Journal of Biological Chemistry.

[28]  M. J. Clague,et al.  Endocytosis: the DUB version. , 2006, Trends in cell biology.

[29]  I. Prior,et al.  Control of growth factor receptor dynamics by reversible ubiquitination. , 2006, Biochemical Society transactions.

[30]  J. Martin-Serrano,et al.  Interaction of AMSH with ESCRT-III and Deubiquitination of Endosomal Cargo* , 2006, Journal of Biological Chemistry.

[31]  M. Komada,et al.  A Deubiquitinating Enzyme UBPY Regulates the Level of Protein Ubiquitination on Endosomes , 2006, Traffic.

[32]  I. Prior,et al.  The Ubiquitin Isopeptidase UBPY Regulates Endosomal Ubiquitin Dynamics and Is Essential for Receptor Down-regulation* , 2006, Journal of Biological Chemistry.

[33]  Xuejun Jiang,et al.  Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain. , 2006, Molecular cell.

[34]  P. Lehner,et al.  Degradation of Endocytosed Epidermal Growth Factor and Virally Ubiquitinated Major Histocompatibility Complex Class I Is Independent of Mammalian ESCRTII* , 2006, Journal of Biological Chemistry.

[35]  M. Komada,et al.  Regulation of epidermal growth factor receptor down-regulation by UBPY-mediated deubiquitination at endosomes. , 2005, Molecular biology of the cell.

[36]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[37]  A. d’Azzo,et al.  E3 Ubiquitin Ligases as Regulators of Membrane Protein Trafficking and Degradation , 2005, Traffic.

[38]  I. Madshus,et al.  Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. , 2004, Experimental cell research.

[39]  J. McCullough,et al.  AMSH is an endosome-associated ubiquitin isopeptidase , 2004, The Journal of cell biology.

[40]  J. Rigas,et al.  Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Xuejun Jiang,et al.  Grb2 regulates internalization of EGF receptors through clathrin-coated pits. , 2003, Molecular biology of the cell.

[42]  P. Bunn,et al.  Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. , 2002, Seminars in oncology.

[43]  Mark von Zastrow,et al.  Signal transduction and endocytosis: close encounters of many kinds , 2002, Nature Reviews Molecular Cell Biology.

[44]  H. Wiley,et al.  Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. , 2001, Molecular biology of the cell.

[45]  L. Lv,et al.  Silencing USP22 by asymmetric structure of interfering RNA inhibits proliferation and induces cell cycle arrest in bladder cancer cells , 2010, Molecular and Cellular Biochemistry.